Edition:
United Kingdom

PhaseRx Inc (PZRX.OQ)

PZRX.OQ on NASDAQ Stock Exchange Capital Market

0.47USD
19 Jan 2018
Change (% chg)

$-0.00 (-0.19%)
Prev Close
$0.47
Open
$0.48
Day's High
$0.67
Day's Low
$0.46
Volume
992,625
Avg. Vol
222,400
52-wk High
$1.95
52-wk Low
$0.22

Select another date:

Thu, Jan 18 2018

BRIEF-Phaserx Revokes Proposed Distribution Record Date

* PHASERX- REVOKED PROPOSED DISTRIBUTION RECORD DATE AS REQUESTED IN DISTRIBUTION RECORD DATE MOTION, WITHDREW THE MOTION IN BANKRUPTCY COURT-SEC FILING Source text: (http://bit.ly/2DmSNqm) Further company coverage:

BRIEF-PhaseRx Receives Decision From Nasdaq Hearings Panel For Continued Listing Of Shares

* PHASERX RECEIVES DECISION FROM THE NASDAQ HEARINGS PANEL FOR CONTINUED LISTING OF SHARES

BRIEF-PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-ASL from EMA

* PHASERX RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION FOR PRX-ASL FROM EUROPEAN MEDICINES AGENCY Source text for Eikon: Further company coverage:

BRIEF-PhaseRx reports Q3 loss per share $0.23

* PhaseRx reports third quarter 2017 financial results and provides corporate update

BRIEF-Phaserx gets delisting notice from NASDAQ

* Says receipt of delisting notice from NASDAQ informing trading in co's stock will be suspended from NASDAQ at opening of business on Nov 1​ Source text for Eikon: Further company coverage:

BRIEF-Phaserx announces corporate restructuring and review of strategic alternatives

* PhaseRx announces corporate restructuring and review of strategic alternatives

BRIEF-PhaseRx receives Orphan Drug Designation from FDA for PRX-ASL

* PhaseRx receives Orphan Drug Designation from FDA for PRX-ASL for the treatment of Argininosuccinate Lyase Deficiency Source text for Eikon: Further company coverage:

BRIEF-Phaserx reports Q2 loss per share $0.30

* Phaserx reports second quarter 2017 financial results and provides corporate update

Select another date: